Your browser is no longer supported. Please, upgrade your browser.
Prothena Corporation plc
Index- P/E- EPS (ttm)-3.11 Insider Own0.05% Shs Outstand40.25M Perf Week-2.76%
Market Cap2.10B Forward P/E- EPS next Y-2.87 Insider Trans- Shs Float20.72M Perf Month2.86%
Income-124.30M PEG- EPS next Q1.00 Inst Own96.60% Short Float7.26% Perf Quarter91.73%
Sales0.90M P/S2338.24 EPS this Y-43.00% Inst Trans5.33% Short Ratio3.00 Perf Half Y263.50%
Book/sh5.83 P/B8.27 EPS next Y-130.00% ROA-34.40% Target Price60.00 Perf Year275.68%
Cash/sh7.86 P/C6.14 EPS next 5Y-0.60% ROE-57.60% 52W Range9.67 - 67.08 Perf YTD301.33%
Dividend- P/FCF- EPS past 5Y-0.90% ROI-61.10% 52W High-28.14% Beta1.47
Dividend %- Quick Ratio15.00 Sales past 5Y-11.90% Gross Margin- 52W Low398.45% ATR4.79
Employees66 Current Ratio15.00 Sales Q/Q100.00% Oper. Margin- RSI (14)47.38 Volatility8.85% 9.53%
OptionableYes Debt/Eq0.00 EPS Q/Q-54.50% Profit Margin- Rel Volume0.88 Prev Close51.48
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume501.94K Price48.20
Recom1.60 SMA20-8.16% SMA5012.55% SMA200104.33% Volume440,464 Change-6.37%
Jun-18-21Upgrade BofA Securities Underperform → Neutral $12 → $49
Jun-08-21Reiterated Oppenheimer Outperform $45 → $54
May-26-21Initiated Citigroup Buy $39
Feb-26-21Upgrade RBC Capital Mkts Sector Perform → Outperform $14 → $28
Feb-12-21Upgrade Jefferies Hold → Buy $15 → $30
Feb-02-21Upgrade BTIG Research Neutral → Buy $29
Dec-07-20Initiated H.C. Wainwright Buy $22
Jul-09-20Upgrade Oppenheimer Perform → Outperform $16
Nov-19-19Upgrade Evercore ISI In-line → Outperform $14
May-21-18Downgrade Barclays Equal Weight → Underweight $14 → $12
Apr-23-18Downgrade Jefferies Buy → Hold
Apr-05-18Reiterated Barclays Overweight $70 → $50
Nov-20-17Downgrade Wedbush Outperform → Neutral $75 → $55
Sep-29-17Reiterated BTIG Research Buy $80 → $77
Sep-15-17Initiated RBC Capital Mkts Outperform $87
Aug-17-17Initiated Evercore ISI Outperform $83
Jul-11-17Initiated Jefferies Buy
Apr-12-17Initiated Piper Jaffray Overweight $69
Apr-12-17Initiated Cantor Fitzgerald Overweight $86
Mar-02-17Initiated Instinet Buy $87
Jul-26-21 03:27PM  
Jul-20-21 04:05PM  
Jul-17-21 07:37AM  
Jul-16-21 11:40AM  
Jul-14-21 03:21PM  
Jul-13-21 12:22PM  
Jul-12-21 12:45PM  
Jun-24-21 08:30AM  
Jun-18-21 04:53AM  
Jun-10-21 04:19PM  
Jun-09-21 04:58AM  
May-20-21 04:05PM  
May-12-21 03:32PM  
May-11-21 04:05PM  
May-10-21 04:05PM  
May-07-21 04:05PM  
May-04-21 04:05PM  
Apr-28-21 12:33PM  
Apr-18-21 03:05PM  
Apr-15-21 04:05PM  
Apr-07-21 04:05PM  
Apr-05-21 04:05PM  
Mar-29-21 08:22AM  
Mar-25-21 11:37AM  
Mar-24-21 08:00AM  
Mar-23-21 04:29PM  
Mar-13-21 10:30AM  
Mar-11-21 08:19AM  
Mar-08-21 04:05PM  
Feb-24-21 04:05PM  
Feb-12-21 05:11PM  
Feb-11-21 09:19AM  
Feb-05-21 04:05PM  
Feb-04-21 04:05PM  
Feb-03-21 12:30PM  
Feb-01-21 04:15PM  
Dec-09-20 08:00AM  
Dec-04-20 04:05PM  
Nov-27-20 12:25AM  
Nov-16-20 02:56AM  
Nov-05-20 11:13AM  
Nov-04-20 06:35PM  
Oct-28-20 04:05PM  
Oct-21-20 10:48AM  
Oct-20-20 04:05PM  
Oct-02-20 04:05PM  
Sep-29-20 02:35PM  
Sep-15-20 08:30AM  
Sep-11-20 08:30AM  
Sep-08-20 04:05PM  
Sep-05-20 11:31AM  
Sep-03-20 04:05PM  
Sep-02-20 04:05PM  
Aug-06-20 08:10PM  
Aug-05-20 04:05PM  
Aug-03-20 12:09PM  
Jul-30-20 04:05PM  
Jul-28-20 12:33PM  
Jul-10-20 08:34AM  
Jun-19-20 12:47PM  
May-27-20 04:05PM  
May-18-20 07:26AM  
May-06-20 07:45PM  
Apr-29-20 04:05PM  
Apr-28-20 12:33PM  
Apr-24-20 04:30PM  
Apr-22-20 09:15AM  
Apr-21-20 10:20AM  
Apr-03-20 04:05PM  
Mar-31-20 04:05PM  
Mar-13-20 11:30AM  
Mar-03-20 04:05PM  
Feb-17-20 06:31PM  
Feb-13-20 10:45AM  
Feb-12-20 05:35PM  
Feb-05-20 04:05PM  
Jan-20-20 11:21AM  
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HENNEY CHRISTOPHER SDirectorJul 14Option Exercise11.3311,108125,85411,108Jul 16 04:02 PM
HENNEY CHRISTOPHER SDirectorJul 14Sale55.4611,108616,0200Jul 16 04:02 PM
HENNEY CHRISTOPHER SDirectorJul 12Option Exercise9.7923,892233,94617,500Jul 12 09:37 PM
HENNEY CHRISTOPHER SDirectorJul 12Sale55.5123,8921,326,1280Jul 12 09:37 PM
HENNEY CHRISTOPHER SDirectorJun 25Option Exercise16.4312,000197,16012,000Jun 29 06:13 PM
HENNEY CHRISTOPHER SDirectorJun 25Sale47.7312,000572,8190Jun 29 06:13 PM
Zago Wagner M.Chief Scientific OfficerJun 22Option Exercise17.81115,2502,052,940115,250Jun 24 04:38 PM
Zago Wagner M.Chief Scientific OfficerJun 22Sale46.15115,2505,318,7690Jun 24 04:38 PM
EcoR1 Capital, LLC10% OwnerMar 24Buy20.75875,00018,156,25011,034,280Mar 25 11:14 AM
EcoR1 Capital, LLC10% OwnerFeb 24Buy22.0210,800237,86710,159,280Feb 25 06:00 PM
EcoR1 Capital, LLC10% OwnerFeb 23Buy21.0544,400934,51810,148,480Feb 25 06:00 PM
Zago Wagner M.Chief Scientific OfficerFeb 18Option Exercise6.417,54048,3317,540Feb 19 06:39 PM
EcoR1 Capital, LLC10% OwnerFeb 18Buy3.6844,100162,10310,104,080Feb 22 04:24 PM
Zago Wagner M.Chief Scientific OfficerFeb 18Sale25.507,540192,2700Feb 19 06:39 PM
EcoR1 Capital, LLC10% OwnerFeb 17Buy23.46198,8404,665,54210,059,980Feb 17 07:14 PM
EcoR1 Capital, LLC10% OwnerFeb 16Buy22.7889,2002,031,9679,861,140Feb 17 07:14 PM
Zago Wagner M.Chief Scientific OfficerFeb 12Option Exercise11.4826,310302,14718,750Feb 17 06:47 PM
EcoR1 Capital, LLC10% OwnerFeb 12Buy20.16345,3006,959,7619,771,940Feb 17 07:14 PM
Zago Wagner M.Chief Scientific OfficerFeb 12Sale19.1626,310504,0570Feb 17 06:47 PM
Kinney Gene G.President and CEOAug 17Option Exercise6.4110,00064,10012,793Aug 19 04:31 PM